Abidi, M. H., Agarwal, R., Ayash, L., Deol, A., Al-Kadhimi, Z., Abrams, J., et al. (2012). Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase i trial. Biol. Blood Marrow Transplant. 18, 1455–1461. doi: 10.1016/j.bbmt.2012.03.010

Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., and Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl. Cancer Inst. 102, 14–25. doi: 10.1093/jnci/djp440

Alifano, M., Mansuet-Lupo A., Lococo, F., Roche, N., Bobbio, A., Canny, E., et al. (2014). Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS ONE 9:e106914. doi: 10.1371/journal.pone.0106914

Alloatti, G., Penna, C., Gallo, M. P., Levi, R. C., Bombardelli, E., and Appendino, G. (1998). Differential effects of paclitaxel and derivatives on Guinea pig isolated heart and papillary muscle. J. Pharmacol. Exp. Ther. 284, 561–567.

Amar, D., Burt, M. E., Bains, M. S., and Leung, D. H. (1996). Symptomatic tachydysrhythmias after esophagectomy: incidence and outcome measures. Ann. Thorac. Surg. 61, 1506–1509. doi: 10.1016/0003-4975(96)00111-7

Anderson, J. L., Halperin, J. L., Albert, N. M., Bozkurt, B., Brindis, R. G., Curtis, L. H. et al., (2013). Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61, 1935–1944. doi: 10.1016/j.jacc.2013.02.001

Anselmi, A., Possati, G., and Gaudino, M. (2009). Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann. Thorac. Surg. 88, 326–333. doi: 10.1016/j.athoracsur.2009.01.031

Aoyagi, T., and Matsui, T. (2011). The cardiomyocyte as a source of cytokines in cardiac injury. J. Cell Sci. Ther. 2012, 1–6.

Arai, M., Tomaru, K., Takizawa, T., Sekiguchi, K., Yokoyama, T., Suzuki, T., et al. (1998). Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell. Cardiol. 30, 243–254. doi: 10.1006/jmcc.1997.0588

Arai, Y., Tadokoro, J., and Mitani, K. (2005). Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am. J. Hematol. 78, 317–318. doi: 10.1002/ajh.20303

Arbuck, S. G., Strauss, H., Rowinsky, E., Christian, M., Suffness, M., Adams, J., et al. (1993). A reassessment of cardiac toxicity associated with Taxol. J. Natl. Cancer Inst. Monogr. 29, 117–130.

Aviles, R. J., Martin, D. O., Apperson-Hansen, C., Houghtaling, P. L., Rautaharju, P., Kronmal, R. A., et al. (2003). Inflammation as a risk factor for atrial fibrillation. Circulation 108, 3006–3010. doi: 10.1161/01.CIR.0000103131.70301.4F

Aziz, S. A., Tramboo, N. A., Mohi-ud-Din, K., Iqbal, K., Jalal, S., and Ahmad, M. (1998). Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin. Oncol. 10, 377–378. doi: 10.1016/S0936-6555(98)80033-2

Balkwill, F. (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13, 135–141. doi: 10.1016/S1359-6101(01)00020-X

Balkwill, F. (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409–416. doi: 10.1007/s10555-006-9005-3

Balkwill, F. (2009). Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361–371. doi: 10.1038/nrc2628

Beck, M. A. (1999). Selenium and host defence towards viruses. Proc. Nutr. Soc. 58, 707–11. doi: 10.1017/S0029665199000920

Berliner, S., Rahima, M., Sidi, Y., Teplitsky, Y., Zohar, Y., Nussbaum, B., et al. (1990). Acute coronary events following cisplatin-based chemotherapy. Cancer Invest. 8, 583–586. doi: 10.3109/07357909009018924

Bracci, L., Schiavoni, G., Sistigu, A., and Belardelli, F. (2014). Belardelli, immune- based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationalebased combined treatments against cancer. Cell Death Differ. 21, 15–25. doi: 10.1038/cdd.2013.67

Brouty-Boye, D., Kolonias, D., and Lampidis, T. J. (1995). Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cells. Int. J. Cancer. 60, 571–575. doi: 10.1002/ijc.2910600424

Bruins, P., te Velthuis, H., Yazdanbakhsh, A. P., Jansen, P. G., van Hardevelt, F. W., de Beaumont, E. M., et al. (1997). Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C- reactive protein and is associated with postoperative arrhythmia. Circulation 96, 3542–3548. doi: 10.1161/01.CIR.96.10.3542

Bryan-Brown, T. (1932). The pharmacological actions of taxine. Quart. J. Pharmacol. 5, 205–219.

Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., et al. (2015). Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425–2437. doi: 10.1056/NEJMoa15 09388

Byrd, J. C., Brown, J. R., O’Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., and et al. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213–223. doi: 10.1056/NEJMoa1400376

Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., et al. (2015). Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 125, 2497–2506. doi: 10.1182/blood-2014-10-606038

Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al. (2012). 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart. J. 33, 2719–2747. doi: 10.1093/eurheartj/ehs253

Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., et al. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 25, 3991–4008 doi: 10.1200/JCO.2007. 10.9777

Chelu, M. G., Sarma, S., Sood, S., Wang, S., van Oort, R. J., Skapura, D. G., et al. (2009). Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J. Clin. Invest. 119, 1940–1951. doi: 10.1172/JCI37059

Choudhary, S., Hegde, P., Pruitt, J. R., Sielecki, T. M., Choudhary, D., Scarpato, K., et al. (2013). Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis 34, 2891–2899. doi: 10.1093/carcin/bgt239

Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., and Nguyen, L., and et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011–2019. doi: 10.1016/S0140-6736(07)61865-0

Chung, M. K., Martin, D. O., Sprecher, D., Wazni, O., Kanderian, A., Carnes, C. A., et al. (2001). Creactive protein elevation in patients with atrial arrhythmias: inflammatorymechanisms and persistence of atrial fibrillation Circulation 104, 2886–2891. doi: 10.1161/hc4901.101760

Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242. doi: 10.1056/NEJMoa011795

Conway, D. S., Buggins, P., Hughes, E., and Lip, G. Y., (2004). Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J. 148, 462–466. doi: 10.1016/j.ahj.2004.01.026

Craig, S. R., Leaver, H. A., Yap, P. L., Pugh, G. C., and Walker, W. S. (2001). Acute phase responses following minimal access and conventional thoracic surgery. Eur. J. Cardiothorac. Surg. 20, 455–463. doi: 10.1016/S1010-7940(01)00841-7

Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P., and Goldhirsch, A. (2010). Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog. Cardiovasc. Dis. 53, 94–104. doi: 10.1016/j.pcad.2010.05.006

de Forni, M., Malet-Martino, M. C., Jaillais, P., Shubinski, R. E., Bachaud, J. M., Lemaire, L., et al. (1992). Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J. Clin. Oncol. 10, 1795–1801. doi: 10.1200/JCO.1992.10.11.1795

Dobrev, D., Voigt, N., and Wehrens, X. H. (2011). The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc. Res. 89, 734–743. doi: 10.1093/cvr/cvq324

Doherty, K. R., Wappel, R. L., Talbert, D. R., Trusk, P. B., Moran, D. M., Kramer, J. W., et al. (2013). Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol. Appl. Pharmacol. 272, 245–255. doi: 10.1016/j.taap.2013.04.027

Dorr, F. A., Von Hoff, D. D., Kuhn, J. G., Schwartz, R., and Kisner, D. L. (1986). Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Cancer Res. 46, 2562–2565.

Duran, J. M., Makarewich, C. A., Trappanese, D., Gross, P., Husain, S., Dunn, J., et al. (2014). Sorafenib cardiotoxicity increases mortality aftermyocardial infarction. Circ. Res. 114, 1700–1712. doi: 10.1161/CIRCRESAHA.114.303200

Elzarrad, M. K., Mukhopadhyay, P., Mohan, N., Hao, E., Dokmanovic, M., Hirsch, D. S., et al. (2013). Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS ONE 8:e79543. doi: 10.1371/journal.pone.0079543

Erichsen, R., Christiansen, C. F., Mehnert, F., Weiss, N. S., Baron, J. A., and Sorensen, H. T., (2012). Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case–control study. Intern. Emerg. Med. 7, 431–438. doi: 10.1007/s11739-011-0701-9

Eskilsson, J., Albertsson, M., and Mercke, C. (1988). Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother. Oncol. 13, 41–46 doi: 10.1016/0167-8140(88)90296-4

European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., et al. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 31, 2369–2429 doi: 10.1093/eurheartj/ehq278

Farmakis, D., Parissis, J., and Filippatos, G. (2014). Insights into onco- cardiology: atrial fibrillation in cancer. J. Am. Coll. Cardiol. 63, 945–953. doi: 10.1016/j.jacc.2013.11.026

Feliz, V., Saiyad, S., Ramarao, S. M., Khan, H., Leonelli, F., and Guglin, M. (2011). Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin. Cardiol. 34, 356–359. doi: 10.1002/clc.20904

Ferrari, R., Bertini, M., Blomstrom-Lundqvist, C., Dobrev, D., Kirchhof, P., Pappone, C., et al. (2016). An update on atrial fibrillation in 2014: from pathophysiology to treatment. Int. J. Cardiol. 203, 22–29. doi: 10.1016/j.ijcard.2015.10.089

Ferreira, C., Providencia, R., Ferreira, M. J., and Goncalves, L. M. (2015). Atrial fibrillation and noncardiovascular diseases: a systematic review. Arq. Bras. Cardiol. 105, 519–526. doi: 10.5935/abc.20150142

Fildes, J. E., Shaw, S. M., Yonan, N., and Williams, S. G. (2009). The immune system and chronic heart failure: is the heart in control? J. Am. Coll. Cardiol. 53, 1013–1020. doi: 10.1016/j.jacc.2008.11.046

Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., and Perry, M. C., (2005). Cardiotoxicity of cancer therapy. J. Clin. Oncol. 23, 7685–7696. doi: 10.1200/JCO.2005.08.789

Frickhofen, N., Beck, F. J., Jung, B., Fuhr, H. G., Andrasch, H., and Sigmund, M. (2002). Capecitabine can induce acute coronary syndrome similar to 5- fluorouracil. Ann. Oncol. 13, 797–801. doi: 10.1093/annonc/mdf035

Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2011). 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 123, e269–367 doi: 10.1161/CIR.0b013e318214876d

Gaudino, M., Andreotti, F., Zamparelli, R., Di Castelnuovo, A., Nasso, G., Burzotta, F., et al. (2003). The−174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108(Suppl. 1), II195– II199. doi: 10.1161/01.cir.0000087441.48566.0d

Gen, W., Tani, M., Takeshita, J., Ebihara, Y., and Tamaki, K. (2001). Mechanisms of Ca2+ overioad induced by extracellular H2O2 in quiescent isoiated rat cardiomyocytes. Basic Res Cardioi. 96, 623–629. doi: 10.1007/s003950170014

Gertz, M. A. (2017). Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am. J. Hematol. 92, 209–217. doi: 10.1002/ajh.24557

Gómez-Caro, A., Moradiellos, F. J., Ausfn, P., Díaz-Hellín, V., Larrú, E., Pérez-Antón, J. A., et al., (2006). Risk factors foratrial fibrillation after thoracic surgery. Arch. Bronconeumol. 42, 9–13.

Gorelik, J., Vodyanoy, I., Shevchuk, A. I., Diakonov, I. A., Lab, M. J., and Korchev, Y. E., (2003). Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay. FEBS Lett. 548, 74–78. doi: 10.1016/S0014-5793(03)00743-9

Gridelli, C., Cigolari, S., Gallo, C., Manzione, L., Ianniello, G. P., Frontini, L., et al. (2001). Activity and toxicity of gemcitabine and gemcitabinevinorelbine in advanced non-small-cell lung cancer elderly patients Phase II data from the

Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.

Lung Cancer. 31, 277–284. doi: 10.1016/S0169-5002(00)00194-X Gu, J. F. (2015). The research progress on cardiac toxic mechanism of anthracyclines and prevention treatment measures. World Notes Antibiot. 6,

241–248. doi: 10.13461/j.cnki.wna.004903 Guglin, M., Aljayeh, M., Saiyad, S., Ali, R., and Curtis, A. B. (2009). Introducing

a new entity: chemotherapy-induced arrhythmia. Europace 11, 1579–1586.

doi: 10.1093/europace/eup300 Guo, Y., Lip, G. Y., and Apostolakis, S. (2012a). Inflammation in atrial fibrillation.

J. Am. Coll. Cardiol. 60, 2263–2270. doi: 10.1016/j.jacc.2012.04.063 Guo, Y., Tian, Y., Wang, H., Si, Q., Y., and Wang, Lip, G. Y. (2015). Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 147, 109–119.

doi: 10.1378/chest.14-0321 Guo, Y., Xu, F., Lu, T., Duan, Z., and Zhang, Z. (2012b). Interleukin-6 signaling

pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904–910.

doi: 10.1016/j.ctrv.2012.04.007 Gupta, A. K., Maheshwari, A., Tresch, D. D., and Thakur, R. K. (2002).

Cardiac arrhythmias in the elderly. Cardiac. Electrophysiol. Rev. 6, 120–128.

doi: 10.1023/A:1017963928016 Guzzetti, S., Costantino, G., and Fundaro, C. (2002). Systemic inflammation, atrial

fibrillation, and cancer. Circulation 106:e40. Haudek, S. B., Taffet, G. E., Schneider, M. D., and Mann, D. L. (2007).

TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J. Clin. Invest. 117, 2692–2701. doi: 10.1172/JCI29134

Heerdt, P. M., Kant, R., Hu, Z., Kanda, V. A., Christini, D. J., and Malhotra, J. K., et al. (2012). Transcriptomic analysis reveals atrial KCNE1 down- regulation following lung lobectomy. J. Mol. Cell. Cardiol. 53, 350–353. doi: 10.1016/j.yjmcc.2012.05.010

Herman, S. E., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., et al. (2011). Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117, 6287–6296. doi: 10.1182/blood-2011-01-328484

Hernández, M. A. (2006). C-reactive protein and atrial fibrillation. an old marker looking for a new target. Rev. Esp. Cardiol. 59, 94–98. doi: 10.1016/S1885-5857(06)60116-3

Hersey, P., Sosman, J., O’Day, S., Richards, J., Bedikian, A., Gonzalez, R., et al. (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 116, 1526–1534. doi: 10.1002/cncr.24821

Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., et al. (2010). The bruton tyrosine kinase inhibitor PCI-32765 blocks Bcell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U. S. A. 107, 13075–13080 doi: 10.1073/pnas.10045 94107

Hooning, M. J., Botma, A., Aleman, B. M., Baaijens, M. H., Bartelink, H., and Klijn, J. G., et al. (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J. Natl. Cancer Inst. 99, 365–375. doi: 10.1093/jnci/djk064

Hove-Madsen, L., Llach, A., Bayes-Genis, A., Roura, S., Rodriguez Font, E., and Arís, A., et al. (2004). Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes Circulation 110, 1358–1363. doi: 10.1161/01.CIR.0000141296.59876.87

Hrovatin, E., Viel, E., Lestuzzi, C., Tartuferi, L., Zardo, F., Brieda, M., et al. (2006). Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin. J. Cardiovasc. Med. 7, 637–640. doi: 10.2459/01.JCM.0000237914.12915.dd

Hu, Y. F., Liu, C. J., Chang, P. M., Tsao, H. M., Lin, Y. J., Chang, S. L., et al., (2013). Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int. J. Cardiol. 165, 355–357. doi: 10.1016/j.ijcard.2012.08.036

Ifran, A., Kaptan, K., and Beyan, C. (2005). High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation. Am. J. Hematol. 80:247. doi: 10.1002/ajh.20441

Illiano, A., Barletta, E., De Marino, V., Battiloro, C., Barzelloni, M., Scognamiglio, F., et al. (2000). New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Anticancer Res. 20, 3999–4003.

Ioannou, K., Cheng, K. F., Crichlow, G. V., Birmpilis, A. I., Lolis, E. J., Tsitsilonis, O. E., et al., (2014). ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models. Int. J. Oncol. 45, 1457–1468. doi: 10.3892/ijo.2014.2551

Issac, T. T., Dokainish, H., and Lakkis, N. M. (2007). Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data, J. Am. Coll. Cardiol. 50, 2021–2028. doi: 10.1016/j.jacc.2007.06.054

Iwasaki, Y. K., Nishida, K., Kato, T., and Nattel, S. (2011). Atrial fibrillation pathophysiology: implications for management. Circulation 124, 2264–2274. doi: 10.1161/CIRCULATIONAHA.111.019893

Jaworski, C., Mariani, J. A., Wheeler, G., and Kaye, D. M. (2013). Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol. 61, 2319–2328. doi: 10.1016/j.jacc.2013.01.090

Jones, A. L., Barlow, M., Barrett-Lee, P. J., Canney, P. A., Gilmour, I. M., Robb, S. D., et al. (2009). Management of cardiac health in trastuzumab- treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer 100, 684–692. doi: 10.1038/sj.bjc.6604909

Karayiannakis, A. J., Syrigos, K. N., Polychronidis, A., Pitiakoudis, M., Bounovas, A., and Simopoulos, K. (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 21, 1355–1358.

Kawabata, M., Umemoto, N., Shimada, Y., Nishimura, Y., Zhang, B., Kuroyanagi, J., et al. (2015). Downregulation of stanniocalcin 1 is responsible for sorafenib- induced cardiotoxicity. Toxicol. Sci. 143, 374–384. doi: 10.1093/toxsci/kfu235

Keefe, D. (2001). Anthracyciine-Induced cardiomyopathy. Semin Oncol. 28(4 Supp12), 2–7. doi: 10.1053/sonc.2001.26431

Keefe, D. L., Roistacher, N., and Pierri, M. K. (1993). Clinical cardiotoxicity of 5-fluorouracil. J. Clin. Pharmacol. 33, 1060–1070. doi: 10.1002/j.1552-4604.1993.tb01943.x

Khan, M. A., Ahmed, F., Neyses, L., and Mamas, M. A. (2013). Atrial fibrillation in heart failure: the sword of Damocles revisited. World J. Cardiol. 5, 215–227. doi: 10.4330/wjc.v5.i7.215

Kilickap, S., Barista, I., Akgul, E., Aytemir, K., Aksoy, S., and Tekuzman, G. (2007). Early and late arrhythmogenic effects of doxorubicin. South. Med. J. 100, 262–265. doi: 10.1097/01.smj.0000257382.89910.fe

Kindt, N., Laurent, G., Nonclercq, D., Journe, F., Ghanem, G., and Duvillier, H., et al. (2013). Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells. Int. J. Oncol. 43, 185–193. doi: 10.3892/ijo.2013.1944

Klein, U., Kosely, F., Hillengass, J., Hundemer, M., Schmitt, S., Neben, K., et al. (2009). Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann. Hematol. 88, 67–71. doi: 10.1007/s00277-008-0561-1

Kluza, J., Marchetti, P., Gallego, M. A., Lancel, S., Fournier, C., Loyens, A., et al. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23, 7018–7030. doi: 10.1038/sj.onc.1207936

Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., et al. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111, 2516–2520. doi: 10.1182/blood-2007-10-116129

Kupari, M., Volin, L., Suokas, A., Timonen, T., Hekali, P., and Ruutu, T. (1990). Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 5, 91–98

Lai, H. C., Yeh, Y. C., Wang, L. C., Ting, C. T., Lee, W. L., Lee, H. W., and et al. (2011). Propofol ameliorates doxorubicin-induced oxidative stress and cellular apoptosis in rat cardiomyocytes. Toxicol. Appl. Pharmacol. 257, 437–448. doi: 10.1016/j.taap.2011.10.001

Lara, P. N., Mack, P. C., Synold, T., Frankel, P., Longmate, J., and Gumerlock, P. H., et al. (2005).The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin. Cancer Res. 11, 4444–4450. doi: 10.1158/1078-0432.CCR-04-2602

Lau, D. H., Psaltis, P. J., Mackenzie, L., Kelly, D. J., Carbone, A., Worthington, M., et al. (2011). Atrial remodeling in an ovine model of anthracycline-induced nonischemic cardiomyopathy: remodeling of the same sort. J. Cardiovasc. Electrophysiol. 22, 175–182. doi: 10.1111/j.1540-8167.2010.01851.x

Lebedinsky, C., Gómez, J., Park, Y. C., Nieto, A., Soto-Matos, A., Parekh, T., and et al. (2011). Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis. Cancer Chemother. Pharmacol. 68, 1223–1231. doi: 10.1007/s00280-011-1614-z

Lee, A. Y. (2005). Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis. Mon. 51, 150–157. doi: 10.1016/j.disamonth.2005.03.010

Lee, J. Y., Lee, H. T., Shin, W., Chae, J., Choi, J., Kim, S. H., and et al. (2016). Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat. Commun. 7:13354. doi: 10.1038/ncomms13354

Lee, S. H., Chen, Y. C., Chen, Y. J., Chang, S. L., Tai, C. T., Wongcharoen, W., et al. (2007). Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci. 80, 1806–1815. doi: 10.1016/j.lfs.2007.02.029

Lenihan, D. J., Alencar, A. J., Yang, D., Kurzrock, R., Keating, M. J., and Duvic, M. (2004). Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104, 655–658. doi: 10.1182/blood-2003-07-2345

Leong, D. P., Caron, F., Hillis, C., Duan, A., Healey, J. S., and Fraser, G., et al. (2016). The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 128, 138–140. doi: 10.1182/blood-2016-05-712828

Liu, Y., Tan, D., Shi, L., Liu, X., Zhang, Y., Tong, C., et al. (2015). Blueberry anthocyaninsenriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS ONE 10:e0127813. doi: 10.1371/journal.pone.0127813

Ma, H., Jones, K. R., Guo, R., Xu, P., Shen, Y., and Ren, J. (2010). Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress, Clin. Exp. Pharmacol. Physiol. 37, 460–465. doi: 10.1111/j.1440-1681.2009.05323.x

Ma, J. Y., Wang, Y., Zhao, Y. F., Wu, Z., Liu, L. X., Kou, Y. L., et al. (2006). Atrial fibrillation after surgery for esophageal carcinoma: clinical and prognostic significance. World J. Gastroenterol. 12, 449–452. doi: 10.3748/wjg.v12.i3.449

Mawhinney, L., Armstrong, M. E., OR, C., Bucala, R., Leng, L., and Fingerle-Rowson, G, et al. (2014). Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Mol. Med. 20, 729–735. doi: 10.2119/molmed.2014.00136

Mc Cormack, O., Zaborowski, A., King, S., Healy, L., Daly, C., O’Farrell, N., et al. (2014). Newonset atrial fibrillation post-surgery for esophageal and junctional cancer: incidence, management, and impact on short- and long-term outcomes. Ann. Surg. 260, 772–778, discussion. 8. doi: 10.1097/SLA.0000000000000960

McMullen, J. R., Boey, E. J., Ooi, J. Y., Seymour, J. F., Keating, M. J., and Tam, C. S. (2014). Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 124, 3829–3830. doi: 10.1182/blood-2014-10-604272

Mego, M., Reckova, M., Obertova, J., Sycova-Mila, Z., Brozmanova, K., and Mardiak, J. (2007). Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 18, 1906–1907. doi: 10.1093/annonc/mdm489

Menard, O., Martinet, Y., and Lamy, P. (1991). Cisplatin-induced atrial fibrillation. J. Clin. Oncol. 9, 192–193 doi: 10.1200/JCO.1991.9.1.192

Mery, B., Guichard, J. B., Guy, J. B., Vallard, A., Barthelemy, J. C., and Da Costa, A., et al. (2017). Atrial fibrillation in cancer patients: hindsight, insight and foresight. Int. J. Cardiol. 240, 196–202 doi: 10.1016/j.ijcard.2017. 03.132

Meydan, N., Kundak, I., Yavuzsen, T., Oztop, I., Barutca, S., Yilmaz, U., et al. (2005). Cardiotoxicity of de gramont’s regimen: incidence, clinical characteristics and long-term follow-up. Jpn. J. Clin. Oncol. 35, 265–270.

Montella, L., Caraglia, M., Addeo, R., Costanzo, R., Faiola, V., Abbruzzese, A., and et al. (2005). Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy. Ann. Hematol. 84, 192–193. doi: 10.1007/s00277-004-0867-6

Moreau, P., Milpied, N., Mahé, B., Juge-Morineau, N., Rapp, M. J., Bataille, R., et al. (1999). Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 23, 1003–1006. doi: 10.1038/sj.bmt.1701763

Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457–1467. doi: 10.1056/NEJMra1100265

Nattel, S. (2002). New ideas about atrial fibrillation 50 years on. Nature 415, 219–226. doi: 10.1038/415219a

Nattel, S., Burstein, B., and Dobrev, D. (2008). Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm Electrophysiol. 1, 62–73. doi: 10.1161/CIRCEP.107.754564

Neben, K., Moehler, T., Benner, A., Kraemer, A., Egerer, G., Ho, A. D., et al. (2002). Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res. 8, 3377–3382.

Neef, S., Dybkova, N., Sossalla, S., Ort, K. R., Fluschnik, N., Neumann, K., et al. (2010). CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 106, 1134–1144. doi: 10.1161/CIRCRESAHA.109.203836

Numico, G., Castiglione, F., Granetto, C., Garrone, O., Mariani, G., Costanzo, G. D., et al. (2002). Single-agent pegylated liposomal doxorubicin (Caelix⃝R ) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 35, 59–64. doi: 10.1016/S0169-5002(01)00269-0

Ojima, T., Iwahashi, M., Nakamori, M., Nakamura, M., Katsuda, M., and Iida, T., et al. (2014). Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg. Today 44, 839–847. doi: 10.1007/s00595-013-0616-3

Olivieri, A., Corvatta, L., Montanari, M., Brunori, M., Offidani, M., Ferretti, G. F., et al. (1998). Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 21, 1049–1053. doi: 10.1038/sj.bmt.1701217

O’Neal, W. T., Lakoski, S. G., Qureshi, W., Judd, S. E., Howard, G., Howard, V. J., et al. (2015). Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am. J. Cardiol. 115, 1090–1094. doi: 10.1016/j.amjcard.2015.01.540

O’Reilly, C., Doroudian, M., Mawhinney, L., and Donnelly, S. C. (2016). Targeting MIF in cancer: therapeutic strategies, current developments, and future opportunities. Med. Res. Rev. 36, 440–460. doi: 10.1002/med.21385

Ott, A., Breteler, M. M., de Bruyne, M. C., van Harskamp, F., Grobbee, D. E., and Hofman, A., (1997). Atrial fibrillation and dementia in a population-based study. the rotterdam study. Stroke 28, 316–321. doi: 10.1161/01.STR.28.2.316

Ozaki, M., Deshpande, S. S., Angkeow, P., Bellan, J., Lowenstein, C. J., Dinauer, M. C., et al. (2000). Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J. 14, 418–429. doi: 10.1096/fasebj.14.2.418

Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., et al. (2008). Prevention of thalidomide and lenalidomide associated trombosis in myeloma. Leukemia. 22, 414–423. doi: 10.1038/sj.leu.2405062

Pérez Persona, E., Mesa, M. G., García Sánchez, P. J., and González Rodríguez, A. P. (2011). Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv. Ther. 28, 11–16. doi: 10.1007/s12325-010-0102-x

Perez-Verdia, A., Angulo, F., Hardwicke, F. L., and Nugent, K. M. (2005). Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 25, 1271–1276. doi: 10.1592/phco.2005.25.9.1271

Petrella, V., Alciato, P., Cantone, P. A., Fico, D., Gagliardini, R., (1989). High-frequency supraventricular arrhythmias induced by a cisplatin-etoposide combination. Minerva Med. 80, 305–307

Pfister, D. G., Su, Y. B., Kraus, D. H.,Wolden, S. L., Lis, E., Aliff, T. B., et al. (2006). Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combinedmodality paradigm. J. Clin. Oncol. 24, 1072–1078. doi: 10.1200/JCO.2004.00.1792

Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M. R., Watkins, C. J., et al. (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2, 721–728.

Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., and Kaneko, S., et al. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560–570. doi: 10.1172/JCI32453

Pretorius, L., Du, X. J., Woodcock, E. A., Kiriazis, H., Lin, R. C., Marasco S., et al. (2010). Reduced phosphoinositide 3-kinase (p110a) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175, 998–1009. doi: 10.2353/ajpath.2009.090126

Priori, S. G., Blomstrom-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., et al. (2015). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patientswith ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 36, 2793–2867 doi: 10.1093/eurheartj/ ehv316

Qi, H. T., and Zhang, X. T. (2015). Advance in research of mechanism, prevention and treatment of radiation-induced cardiac toxicity in cancer patients. Chin. Jo. Cancer Prevent. Treat. 10, 814–818.

Qu,Y.C.,Du,Y.M.,Wu,S.L.,Chen,Q.X.,Wu,H.L.,andZhou,S.F. (2009). Activated nuclear factor kappaB and increased tumor necrosis factor- alpha in atrial tissue of atrial fibrillation. Scand. Cardiovasc. J. 43, 292–297. doi: 10.1080/14017430802651803

Quezado, Z. M., Wilson, W. H., Cunnion, R. E., Parker, M. M., Reda, D., Bryant, G., et al., (1993). High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann. Intern. Med. 118, 31–36 doi: 10.7326/0003-4819-118-1-199301010-00006

Rao, F., Deng, C. Y., Wu, S. L., Xiao, D. Z., Yu, X. Y., Kuang, S. J., et al. (2009). Involvement of Src in L-type Ca2+channel depression induced bymacrophage migration inhibitory factor in atrial myocytes. J. Mol. Cell. Cardiol. 47, 586–594. doi: 10.1016/j.yjmcc.2009.08.030

Richards, W. G., Zellos, L., Bueno, R., Jaklitsch, M. T., Jänne, P. A., Chirieac, L. R., et al. (2006). Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J. Clin. Oncol. 24, 1561–1567. doi: 10.1200/JCO.2005.04.6813

Robertson, J. F. R. , Cannon, P. M., Nicholson, R. I., and Blamey, R. W. (1996). Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. Int. J. Biol. Mark. 11, 2.

Roselli, E. E., Murthy, S. S., Rice, T. W., Houghtaling, P. L., Pierce, C. D., Karchmer, D. P. et al., (2005). Atrial fibrillation complicating lung cancer resection.J. Thorac. Cardiovasc. Sur. 130, 438–444. doi: 10.1016/j.jtcvs.2005.02.010

Russell, R. R., Alexander, J., Jain, D., Poornima, I. G., Srivastava, A. V., Storozynsky, E., and et al. (2016). The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J. Nucl. Cardiol. 23, 856–884. doi: 10.1007/s12350-016-0538-8

Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., and Fagin, J. A. (2014). Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer. 21, 371–381. doi: 10.1530/ERC-13-0499

Sag, C. M., Köhler, A. C., Anderson, M. E., Backs, J., and Maier, L. S. (2011). CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J. Mol. Cell Cardiol. 51, 749–759. doi: 10.1016/j.yjmcc.2011.07.016

Saif, M. W., Shah, M. M., and Shah, A. R. (2009). Fluoropyrimidine- associated cardiotoxicity: revisited. Expert Opin. Drug Saf. 8, 191–202. doi: 10.1517/14740330902733961

Samman Tahhan, A., Sandesara, P. B., Hayek, S. S., Alkhoder, A., Chivukula, K., Hammadah M., et al. (2017). Association between oxidative stress and atrial fibrillation. Heart Rhythm. 14, 1849–1855. doi: 10.1016/j.hrthm.2017.07.028

Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., et al., (2002). Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718–728.

Schmitt, J., Duray, G., Gersh, B. J., and Hohnloser, S. H. (2009). Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur. Heart. J. 30, 1038–1045. doi: 10.1093/eurheartj/ehn579

Schwartz, R. G., Jain, D., and Storozynsky, E. (2013). Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J. Nucl. Cardiol. 20, 443–464. doi: 10.1007/s12350-013-9707-1

Shanafelt, T. D., Parikh, S. A., Noseworthy, P. A., Goede, V., Chaffee, K. G., and Bahlo, J., et al. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma. 58, 1630–1639. doi: 10.1080/10428194.2016.1257795

Siegel, R. L., Miller, K. D., and Jemal, A. (2016). Cancer statistics 2016. CA Cancer J. Clin. 66, 7–30. doi: 10.3322/caac.21332

Siemes, C., Visser, L. E., Coebergh, J. W., Splinter, T. A., Witteman, J. C., and Uitterlinden, A. G., et al. (2006). C-reactive protein levels, variation in the C- reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 24, 5216–5222. doi: 10.1200/JCO.2006.07.1381

Siu, C. W., Tung, H. M., Chu, K. W., Jim, M. H., Lau, C. P., and Tse, H. F. (2005). Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer. Pacing Clin. Electrophysiol. 28, S120–S123. doi: 10.1111/j.1540-8159.2005.00024.x

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 doi: 10.1126/science.3798106

Stadler, W. M., Margolin, K., Ferber, S., McCulloch, W., and Thompson, J. A. (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer. 5, 57–60. doi: 10.3816/CGC.2006.n.018

Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., et al., (2008). A phase 1Pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14, 804–810. doi: 10.1158/1078-0432.CCR-07-1786

Sudharsan, P. T., Mythili, Y., Selvakumar, E., and Varalakshmi, P. (2006). Lupeol and its ester ameliorate the cyclophosphamide provoked cardiac lysosomal damage studied in rat. Mol. Cell. Biochem. 282, 23–29. doi: 10.1007/s11010-006-1169-1

Szlosarek, P., W., and Balkwill F., R. (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4, 565–573. doi: 10.1016/S1470-2045(03)01196-3

Tamargo, J., Caballero, R., and Delpon, E. (2015). Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 38, 129–152. doi: 10.1007/s40264-014-0258-4

Thompson, J. A., Bianco, J. A., Benyunes, M. C., Neubauer, M. A., Slattery, J. T., and Fefer, A. (1994). Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res. 54, 3436–3441.

Tilleman, T. R., Richards, W. G., Zellos, L., Johnson, B. E., Jaklitsch, M. T., Mueller, J., et al. (2009). Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J. Thorac. Cardiovasc. Surg. 138, 405–411. doi: 10.1016/j.jtcvs.2009.02.046

Tomkowski,W.Z.,Wi ́sniewska,J.,Szturmowicz,M.,Kuca,P.,Burakowski,J., Kober, J., et al. (2004). Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 12, 53–57. doi: 10.1007/s00520-003- 0533-x

Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., et al. (2015). Ibrutinib in previously treated Waldenstreom’s macroglobulinemia. N. Engl. J. Med. 372, 1430–1440. doi: 10.1056/NEJMoa1501548

Ueda, H., Nakajima, H., Hori, Y., Fujita, T., Nishimura, M., Goto, T., et al. (1994a). FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. Taxonomy, I., fermentation, isolation, physicochemical and biological properties, and antitumor activity. J. Antibiot. 47, 301–310. doi: 10.7164/antibiotics.47.301

Ueda, H., Nakajima, H., Hori, Y., Goto, T., and Okuhara, M. (1994b). Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58, 1579–1583. doi: 10.1271/bbb.58.1579

van der Vorst, E. P., Doring, Y., and Weber, C. (2015). MIF and CXCL12 in cardiovascular diseases: functional differences and similarities. Front. Immunol. 6:373. doi: 10.3389/fimmu.2015.00373

Vaporciyan, A. A., Correa, A. M., Rice, D. C., Roth, J. A., Smythe, W. R., Swisher, S. G., et al. (2004). Risk factors associated with atrial fibrillation after noneardiac thoracic surgery:analysis of 2588 patients. J. Thorac. Cardiovasc. Surg. 127, 779–786. doi: 10.1016/j.jtcvs.2003.07.011

Varga, Z. V., Ferdinandy, P., Liaudet, L., and Pacher, P. (2015). Drug-induced mitochondrial dysfunction and cardiotoxicity. Am. J. Phys. Heart Circ. Phys. 309, H1453–H1467. doi: 10.1152/ajpheart.00554.2015

Varinelli, L., Caccia, D., Volpi, C. C., Caccia, C., De Bortoli, M., Taverna, E., et al. (2015). 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. Endocr. Relat. Cancer 22, 759–775. doi: 10.1530/ERC-15-0299

Veronesi, U., Maisonneuve, P., Rotmensz, N., Bonanni, B., Boyle, P., Viale, G., et al. (2007). Tamoxifen for the prevention of breast cancer: late results of the italian randomized tamoxifen prevention trial among women with hysterectomy. J. Natl. Cancer Inst. 99, 727–737. doi: 10.1093/jnci/djk154

Vest, J. A., Wehrens, X. H., Reiken, S. R., Lehnart, S. E., Dobrev, D., Chandra, P., et al. (2005). Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111, 2025–2032. doi: 10.1161/01.CIR.0000162461.67140.4C

Voigt, N., Heijman, J., Wang, Q., Chiang, D. Y., Li, N., Karck, M., et al. (2014). Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 129, 145–156. doi: 10.1161/CIRCULATIONAHA.113.006641

Voigt, N., Li, N., Wang, Q., Wang, W., Trafford, A. W., Abu-Taha, I., et al. (2012). Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 125, 2059–2070. doi: 10.1161/CIRCULATIONAHA.111.067306

Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., et al. (2015). Long-term follow-up of MCL patients treated with single- agent ibrutinib:updated safety and efficacy results. Blood. 126, 739–745. doi: 10.1182/blood-2015-03-635326

Wang, Z. X., Wang, H. Q., Cheng, J., et al. (2018). Research progress on pathogenesis of atrial fibrillation. China Medical Herald. 15, 26–29.

Weber, D., Rankin, K., Gavion, M., Dalasalle, K., and Alexanian, R. (2003). Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21, 16–19. doi: 10.1200/JCO.2003.03.139

White, R. L., Schwartzentruber, D. J., Guleria, A., MacFarlane, M. P., White, D. E., Tucker, E., et al. (1994). Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer. 74, 3212–3222.

Will, Y., Dykens, J. A., Nadanaciva, S., Hirakawa, B., Jamieson, J., Marroquin, L. D., and et al. (2008). Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153–161. doi: 10.1093/toxsci/kfn157

Wolchok, J. D. (2015). PD-1 blockers. Cell. 162:937. doi: 10.1016/j.cell.2015.07.045 Woolley, P. V., Ayoob, M. J., Levenson, S. M., and Smith, F. P. (1982). A phase I clinical trial of aclacinomycin A administered on a five-consecutive- day sychedule. J. Clin. Pharmacol. 22, 359–365.

doi: 10.1002/j.1552-4604.1982.tb02686.x Xin, Y., Zhang, S., Gu, L., Liu, S., Gao, H., You, Z., et al. (2011).

Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs. Biol. Pharm. Bull. 34, 1523–1526. doi: 10.1248/bpb.34.1523

Xing, Y., Gao, Y., Chen, J., Zhu, H., Wu, A., Yang, Q., et al. (2013). Wenxin-Keli regulates the calcium/calmodulin-dependent protein kinase ii signal transduction pathway and inhibits cardiac arrhythmia in rats with myocardial infarction. Evid. Based Complement. Alternat. Med, 2013:464508. doi: 10.1155/2013/464508

Yang, T., Moleslehi, J., and Roden, D. M. (2015). Proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton’S tyrosine kinase (BTK) used in cancer therapy. Circulation 132(Supp. 3):A14587. doi: 10.1161/circ.132.suppl_3.14587

Yang, X., Li, Y., Li, Y., Ren, X., Zhang, X., Hu, D., et al. (2017a). Oxidative stress- mediated atherosclerosis: mechanisms and therapies. Front. Physiol. 8:600. doi: 10.3389/fphys.2017.00600

Yang, X., Yu, C., Li, Y., Ren, X., Xing, Y., and Shang, H. (2017b). Effects of Wenxin Keli on cardiac hypertrophy and arrhythmia via regulation of the calcium/calmodulin dependent kinase ii signaling pathway. Biomed. Res. Int. 2017:1569235. doi: 10.1155/2017/1569235

Yu, C., Chopra, I. J., and Ha, E. (2015). A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinol. Diabetes Metab. Case Rep. 2015:140092. doi: 10.1530/EDM-14-0092

Yun, S., Vincelette, N. D., Acharya, U., and Abraham, I. (2017). Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin. Lymphoma Myeloma Leuk. 17, 31–37. doi: 10.1016/j.clml.2016.09.010

Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A. V., et al. (2001). Increased risk of deep-vein thrombosis in patients with multiple

myeloma receiving thalidomide and chemotherapy. Blood. 98, 1614–1615.

doi: 10.1182/blood.V98.5.1614 Zangari, M., Tricot, G., Polavaram, L., Zhan, F., Finlayson, A., Knight, R.,

et al. (2009). Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone. J. Clin. Oncol. 28, 132–135. doi: 10.1200/JCO.2009. 23.0169

Zellos, L., Richards, W. G., Capalbo, L., Jaklitsch, M. T., Chirieac, L. R., Johnson, B. E., et al. (2009). A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 137, 453–458. doi: 10.1016/j.jtcvs.2008.07.055

Zhang, H., Zhang, A., Guo, C., Shi, C., Zhang, Y., Liu, Q., et al. (2011). S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. PLoS ONE 6:e26441. doi: 10.1371/journal.pone.0026441

Zhang, Y., Wang, Y. T.,Shan, Z. L., Guo, H. Y., Guan, Y., and Yuan, H. T. (2015). Role of inflammation in the initiation andmaintenance of atrial fibrillation and

the protective effect of atorvastatin in a goat model of aseptic pericarditis. Mol.

Med. Rep. 11, 2615–2623. doi: 10.3892/mmr.2014.3116 Zonder, J. A., Barlogie, B., Durie, B. G., McCoy, J., Crowley, J., and Hussein, M. A.

(2006). Thrombotic complications in patients with newly diagnosed multiple treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 108:403. doi: 10.1182/blood-2006-01-0154